METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First-in-Human trial targets genetic root of fatty liver disease
Disease control Recruiting nowThis is a very early-stage study testing an experimental drug called ALN-PNP in healthy adults and people with a common fatty liver disease (MASLD). The main goal is to check the drug's safety, how the body processes it, and see if it can reduce liver fat. Researchers will also s…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Common vitamin shows promise against silent liver disease
Disease control Recruiting nowThis study is testing whether a common vitamin, niacin (vitamin B3), can help reduce harmful fat buildup in the liver. Researchers will give 36 older adults with fatty liver disease either niacin or a placebo pill for 12-week periods to see if the vitamin helps the body store fat…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: NA • Sponsor: Université de Sherbrooke • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
First human test for promising fatty liver drug begins
Disease control Recruiting nowThis early-stage study is testing whether a new drug called miricorilant can reduce fat buildup in the liver of people with MASH, a serious form of fatty liver disease. Eight participants will take the drug daily for six weeks while researchers measure changes in liver fat produc…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC